Isomorphic Labs's banner

Isomorphic Labs

@IsomorphicLabs • 57,789 subscribers

Solve all disease. Developing and applying frontier AI to unlock deeper scientific insights, faster breakthroughs, and life-changing medicines.

Shorts

We're excited to announce #AlphaFold 3 with Google DeepMind in nature: our new AI model for predicting biomolecule structures with unprecedented breadth and accuracy. Expanding beyond proteins to tackle DNA, RNA, small molecules to fuel advances in biology & drug design 🧵

We're excited to announce #AlphaFold 3 with Google DeepMind in nature: our new AI model for predicting biomolecule structures with unprecedented breadth and accuracy. Expanding beyond proteins to tackle DNA, RNA, small molecules to fuel advances in biology & drug design 🧵

296,943 views

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients. Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine. Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine. Read the full announcement here:

Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients. Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine. Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine. Read the full announcement here:

Isomorphic Labs

272,250 views • 1 month ago

We recently released a technical report highlighting how Isomorphic Labs’ drug design engine is achieving a step change in how we model complex biological mechanisms, consistently outperforming industry benchmarks. Read our blog to discover how we’re bridging the gap between structure prediction and rational drug design. You can find the link in the comments.

We recently released a technical report highlighting how Isomorphic Labs’ drug design engine is achieving a step change in how we model complex biological mechanisms, consistently outperforming industry benchmarks. Read our blog to discover how we’re bridging the gap between structure prediction and rational drug design. You can find the link in the comments.

Isomorphic Labs

125,087 views • 3 months ago

“One of the great things about Iso is how interdisciplinary everyone is, people come from so many different backgrounds.” We spoke with Bilal Khan, Software Engineer at Isomorphic Labs, about our unique, collaborative culture and frontier AI built to tackle the world's most complex problems. Watch the video and head to the comments to explore our current roles.

“One of the great things about Iso is how interdisciplinary everyone is, people come from so many different backgrounds.” We spoke with Bilal Khan, Software Engineer at Isomorphic Labs, about our unique, collaborative culture and frontier AI built to tackle the world's most complex problems. Watch the video and head to the comments to explore our current roles.

Isomorphic Labs

19,571 views • 3 months ago

How could #AlphaFold 3 transform drug discovery? Most drugs are small molecules known as ligands that bind to proteins to change how they interact in human health and disease. AlphaFold 3 can predict these interactions to atomic accuracy.

How could #AlphaFold 3 transform drug discovery? Most drugs are small molecules known as ligands that bind to proteins to change how they interact in human health and disease. AlphaFold 3 can predict these interactions to atomic accuracy.

Isomorphic Labs

75,322 views • 2 years ago

Check out 'Inside Iso', our new video series taking people inside Isomorphic Labs, and learn what keeps our 'Isos' intrigued as we work to change the way drug discovery is done. Join us! #AI #machinelearning #drugdiscovery

Check out 'Inside Iso', our new video series taking people inside Isomorphic Labs, and learn what keeps our 'Isos' intrigued as we work to change the way drug discovery is done. Join us! #AI #machinelearning #drugdiscovery

Isomorphic Labs

30,373 views • 3 years ago

“Some of these research problems we’ve been going after really are holy grail predictive problems for drug design - and we’ve made some incredible breakthroughs there, which have really stunned our chemists.” On Sequoia Capital’s Training Data podcast, our Chief AI Officer Max Jaderberg talks about the scale of AI drug discovery and its potential to transform how we design new medicines. Listen to the full podcast at the link below:

“Some of these research problems we’ve been going after really are holy grail predictive problems for drug design - and we’ve made some incredible breakthroughs there, which have really stunned our chemists.” On Sequoia Capital’s Training Data podcast, our Chief AI Officer Max Jaderberg talks about the scale of AI drug discovery and its potential to transform how we design new medicines. Listen to the full podcast at the link below:

Isomorphic Labs

12,294 views • 1 year ago

No more content to load